Bionomics Limited - Product Pipeline Review - 2015

Date: November 18, 2015
Pages: 45
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BDC687CCD9BEN
Leaflet:

Download PDF Leaflet

Bionomics Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Bionomics Limited - Product Pipeline Review - 2015’, provides an overview of the Bionomics Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bionomics Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Bionomics Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Bionomics Limited’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Bionomics Limited’s pipeline products
Reasons to buy
  • Evaluate Bionomics Limited’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Bionomics Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Bionomics Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Bionomics Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bionomics Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Bionomics Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Bionomics Limited Snapshot
Bionomics Limited Overview
Key Information
Key Facts
Bionomics Limited - Research and Development Overview
Key Therapeutic Areas
Bionomics Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Bionomics Limited - Pipeline Products Glance
Bionomics Limited - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Bionomics Limited - Early Stage Pipeline Products
IND/CTA Filed Products/Combination Treatment Modalities
Preclinical Products/Combination Treatment Modalities
Bionomics Limited - Drug Profiles
BNC-105
Product Description
Mechanism of Action
R&D Progress
BNC-210
Product Description
Mechanism of Action
R&D Progress
BNC-101
Product Description
Mechanism of Action
R&D Progress
BL-011256
Product Description
Mechanism of Action
R&D Progress
BNC-164
Product Description
Mechanism of Action
R&D Progress
BNC-420
Product Description
Mechanism of Action
R&D Progress
Drug for Dyskinesia
Product Description
Mechanism of Action
R&D Progress
Drug for Pain
Product Description
Mechanism of Action
R&D Progress
Drugs for Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit MELK for Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize GABA-A Receptor for Epilepsy
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain
Product Description
Mechanism of Action
R&D Progress
Bionomics Limited - Pipeline Analysis
Bionomics Limited - Pipeline Products by Target
Bionomics Limited - Pipeline Products by Route of Administration
Bionomics Limited - Pipeline Products by Molecule Type
Bionomics Limited - Pipeline Products by Mechanism of Action
Bionomics Limited - Recent Pipeline Updates
Bionomics Limited - Dormant Projects
Bionomics Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Drug to Inhibit RET Kinase for Lung and Thyroid Cancer
Bionomics Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Bionomics Limited, Key Information
Bionomics Limited, Key Facts
Bionomics Limited - Pipeline by Indication, 2015
Bionomics Limited - Pipeline by Stage of Development, 2015
Bionomics Limited - Monotherapy Products in Pipeline, 2015
Bionomics Limited - Out-Licensed Products in Pipeline, 2015
Bionomics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015
Bionomics Limited - Phase II, 2015
Bionomics Limited - Phase I, 2015
Bionomics Limited - IND/CTA Filed, 2015
Bionomics Limited - Preclinical, 2015
Bionomics Limited - Pipeline by Target, 2015
Bionomics Limited - Pipeline by Route of Administration, 2015
Bionomics Limited - Pipeline by Molecule Type, 2015
Bionomics Limited - Pipeline Products by Mechanism of Action, 2015
Bionomics Limited - Recent Pipeline Updates, 2015
Bionomics Limited - Dormant Developmental Projects,2015
Bionomics Limited - Discontinued Pipeline Products, 2015
Bionomics Limited, Subsidiaries

LIST OF FIGURES

Bionomics Limited - Pipeline by Top 10 Indication, 2015
Bionomics Limited - Pipeline by Stage of Development, 2015
Bionomics Limited - Monotherapy Products in Pipeline, 2015
Bionomics Limited - Pipeline by Top 10 Target, 2015
Bionomics Limited - Pipeline by Top 10 Route of Administration, 2015
Bionomics Limited - Pipeline by Top 10 Molecule Type, 2015
Bionomics Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Bionomics Limited - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: